space invasion, margin distance, and clitoral involvement. 6 – 14 Due to inconsistent definitions and results across studies, most risk factors have not been adopted into current staging systems. The vulvar cancer staging system in the 8th edition of
Search Results
Evaluation of AJCC and an Alternative Tumor Classification System for Primary Vulvar Squamous Cell Carcinoma
Sarah T. Le, Pritesh S. Karia, Beverley J. Vollenhoven, Robert J. Besaw, Colleen M. Feltmate, and Chrysalyne D. Schmults
HSR19-092: Adjuvant Radiotherapy Is Associated with Improved Overall Survival for Resected Alveolar Ridge Squamous Cell Carcinoma With Adverse Pathologic Features
Corbin D. Jacobs, Daniel J. Rocke, Russel R. Kahmke, Hannah Williamson, Gita Suneja, and Yvonne M. Mowery
-defined risk factors (positive margin, lymphovascular invasion, pT3–4, N2–3, extranodal extension, or level IV/V nodal metastasis), and unknown/missing NCCN risk factor data. Log-rank test stratified by RT and Cox regression analyses with respect to OS were
Diagnosis and Management of Rectal Cancer in Patients Younger Than 50 Years: Rising Global Incidence and Unique Challenges
Daenielle Lang and Kristen K. Ciombor
that will impact potential outcomes; and (4) unique challenges facing this patient population. Epidemiology and Risk Factors Similar to CRC as a whole, the incidence of rectal cancer in all ages has been decreasing since the 1980s; it has
Letter to the Editor: Radiation for Prior DCIS is a Risk Factor for Death From Invasive Breast Cancer
Victoria Sopik, Vasily Giannakeas, and Steven Narod
Breast Cancer Risk Reduction
Therese B. Bevers, Deborah K. Armstrong, Banu Arun, Robert W. Carlson, Kenneth H. Cowan, Mary B. Daly, Irvin Fleming, Judy E. Garber, Mary Gemignani, William J. Gradishar, Helen Krontiras, Swati Kulkarni, Christine Laronga, Loretta Loftus, Deborah J. MacDonald, Martin C. Mahoney, Sofia D. Merajver, Ingrid Meszoely, Lisa Newman, Elizabeth Pritchard, Victoria Seewaldt, Rena V. Sellin, Charles L. Shapiro, and John H. Ward
the United States in 2010. 1 Risk factors for the development of breast cancer can be grouped into categories, including familial/genetic factors (family history, known or suspected BRCA1/2, TP53, PTEN , or other gene mutation associated with breast
Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
Jeffrey Crawford, Pamela Sue Becker, James O. Armitage, Douglas W. Blayney, Julio Chavez, Peter Curtin, Shira Dinner, Thomas Fynan, Ivana Gojo, Elizabeth A. Griffiths, Shannon Hough, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Mary Mably, Sudipto Mukherjee, Shiven Patel, Lia E. Perez, Adam Poust, Raajit Rampal, Vivek Roy, Hope S. Rugo, Ayman A. Saad, Lee S. Schwartzberg, Sepideh Shayani, Mahsa Talbott, Saroj Vadhan-Raj, Sumithira Vasu, Martha Wadleigh, Peter Westervelt, Jennifer L. Burns, and Lenora Pluchino
-Hodgkin's lymphoma (NHL) has shown that the rates of myelosuppression and delivered dose intensity are underreported. 4 Due to individual patient risk factors, the rates of myelosuppression with the same or similar regimens varied greatly, making it difficult to
Outcomes and Predictors of 28-Day Mortality in Patients With Hematologic Malignancies and Septic Shock Defined by Sepsis-3 Criteria
Nirmala K. Manjappachar, John A. Cuenca, Claudia M. Ramírez, Mike Hernandez, Peyton Martin, Maria P. Reyes, Alba J. Heatter, Cristina Gutierrez, Nisha Rathi, Charles L. Sprung, Kristen J. Price, and Joseph L. Nates
; APL, acute promyelocytic leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; GVHD, graft-versus-host disease; MM, multiple myeloma. Figure 3. Multivariable analysis of risk factors associated with 28-day mortality (n=456
Clinical Risks for Chronic Lymphocytic Leukemia
Jennifer R. Brown
The risk factors for developing chronic lymphocytic leukemia (CLL) are not well-defined and often cannot be identified in a given individual. Multiple cooperating genes are likely required for CLL development, together with predisposing
Association Between Pretreatment Chest Imaging and Immune Checkpoint Inhibitor Pneumonitis Among Patients With Lung Cancer
Alexander Wong, Maria Riley, Songzhu Zhao, Jessica Zimmer, Matthew Viveiros, Jing Gennie Wang, Vincent Esguerra, Mingjia Li, Gabrielle Lopez, Kari Kendra, David P. Carbone, Kai He, Asrar Alahmadi, Jacob Kaufman, Regan M. Memmott, Peter G. Shields, Jeremy Brownstein, Karl Haglund, Meng Welliver, Gregory A. Otterson, Carolyn J. Presley, Lai Wei, Dwight H. Owen, and Kevin Ho
a result. 11 There are several treatment-dependent risk factors that have been associated with increased likelihood ICI-p, such as dual ICI treatment, 6 , 12 PD-1 ICIs, 12 and prior chemoradiation, 13 but limited evidence for patient
Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
Peter F. Coccia, Alberto S. Pappo, Lynda Beaupin, Virginia F. Borges, Scott C. Borinstein, Rashmi Chugh, Shira Dinner, Jeanelle Folbrecht, A. Lindsay Frazier, Robert Goldsby, Alexandra Gubin, Robert Hayashi, Mary S. Huang, Michael P. Link, John A. Livingston, Yousif Matloub, Frederick Millard, Kevin C. Oeffinger, Diane Puccetti, Damon Reed, Steven Robinson, Abby R. Rosenberg, Tara Sanft, Holly L. Spraker-Perlman, Margaret von Mehren, Daniel S. Wechsler, Kimberly F. Whelan, Nicholas Yeager, Lisa A. Gurski, and Dorothy A. Shead
adequate evaluation of the efficacy of a given treatment regimen, which in turn can invalidate the results of a clinical trial. Risk factors for nonadherence among AYA patients include patients' emotional functioning (depression and poor/low self
